TVT study: 3-year results announced

Article

Three-year results from the Tube versus Trabeculectomy Study showed that tube-shunt surgery was more likely than trabeculectomy with mitomycin C to maintain IOP control and avoid persistent hypotony, loss of light perception vision, or re-operation for glaucoma.

Three-year results from the Tube versus Trabeculectomy Study showed that tube-shunt surgery was more likely than trabeculectomy with mitomycin C to maintain IOP control and avoid persistent hypotony, loss of light perception vision, or re-operation for glaucoma. A highly significant difference between study arms was apparent in the cumulative probability of failure analysis.

The cumulative probability of failure was estimated at 15.1% in the tube group and 30.7% in the trabeculectomy group at three years. The three-year analysis showed that most patients in both groups failed because of inadequate pressure control.

The treatment benefit for tube-shunt surgery was observed despite the findings of no significant difference between study groups in mean IOP and the mean number of glaucoma medications used at the three-year time point.

Visual acuity results in both study groups showed a reduction over the three-year period, and Snellen and Early-Treatment Diabetic Retinopathy Study acuity were similar for both sets of patients.

Although the findings do not demonstrate clear superiority of one glaucoma operation over the other, it was suggested that the role of tube shunts be expanded.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
At this year's ESCRS meeting, we asked presenters and attendees, 'What do yoou wish you'd known earlier in your ophthalmology career?'
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.